Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting May 26, 2026 — Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders —
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences May 21, 2026 – Real-World Evidence of Positive Impact of LYBALVI® (olanzapine and samidorphan) on Treatment Patterns and Rates of Relapse Among Patients with Schizophrenia or Bipolar I Disorder, Including Young Adults – – APA Plenary Presentation Highlights Recent Clinical Data, Including Results for Negative Symptoms and Outcomes From Four Years of Treatment, and Real-World Evidence From Use of LYBALVI (olanzapine and samidorphan) in Clinical Practice –
Xsolla and the Dubai Films and Games Commission Create a Strategic Partnership to Connect Dubai-Based Developers to Global Markets May 21, 2026 Multi-Year Agreement Creates Opportunities to Build All The Things for Video Games in Dubai and MENA
Xsolla Expands Nordic Presence With Industry Engagements Across Sweden, Including Official Sponsorship of Nordic Game 2026 May 20, 2026 Coordinated Activations Across Sweden Underscore Xsolla’s Continued Investment In The Nordic Games Ecosystem, Bringing Developers, Partners, And Creators Together
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June May 19, 2026 LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Phil Kowalczyk, Chief Strategy and Corporate Development Officer, will participate in a fireside chat on [...]
Money20/20 Europe Announces Powerhouse Speaker Lineup Featuring Leaders from Klarna, BBVA, ABN AMRO, Mastercard, eToro, and Revolut May 19, 2026 Leading voices in payments, banking, and fintech innovation to take the stage in Amsterdam
AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026 May 14, 2026 Preclinical AVB-406 data presented in three oral presentations demonstrate the power of the vMiXTM RNAi platform and support planned clinical initiation for Alzheimer’s disease by the end of 2026 Preclinical data show AVB-406 achieved up to 80% MAPT/tau knockdown in the brain
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference May 12, 2026 Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026 at 2:00 p.m. ET. The live webcast can be [...]
Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 2026 May 11, 2026 The MEVION S250-FIT™ creates a new pathway for European cancer centers to integrate proton therapy into existing radiotherapy programs
Prothena Reports First Quarter 2026 Financial Results and Business Highlights May 7, 2026 Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus prior guidance $50 to $55 million) and expects to end the year with approximately $273 million (midpoint) in cash, cash equivalents and restricted cash Novo Nordisk obtained Fast Track designation from the U.S. FDA for coramitug (PRX004) for the treatment of ATTR amyloidosis with cardiomyopathy and paid Prothena a $50 million clinical milestone payment related to Phase 3 enrollment Roche presented several clinical updates supporting the potential of prasinezumab for the treatment of Parkinson’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) Prothena has completed the Phase 1 study for PRX019. Prothena could potentially earn a $55 million clinical milestone payment if Bristol Myers Squibb decides to advance the program; BMS decision expected by year-end 2026 Prothena initiated a share repurchase program to be conducted in 2026 for up to $100 million if deemed appropriate